Biologics

Pipeline

Our top priority is to ensure patient safety and therapeutic efficacy in the development of veterinary mesenchymal stem cell (MSC) based biologics.

Our current pipeline includes advanced development programs designed for canine and equine patients. Two of our products are intended for dogs — one addresses osteoarthritis (OA), while the other is designed to treat atopic dermatitis (AD). A third product targets joint inflammation in horses. In addition, we are conducting research and development on a second atopic dermatitis therapy for dogs, this time using secretome — a mixture of proteins and signaling molecules secreted by stem cells into the extracellular environment.

Our lead product, BCX-CM-J, for the treatment of canine osteoarthritis, is expected to become the world’s first veterinary medicinal product containing allogeneic canine stem cells. A centralized registration procedure is currently ongoing with the European Medicines Agency (EMA).

Product	BCX-CM-J	BCX-EM	BCX-CM-AD
Species
Condition	OA	OA	AD
Route of adminitration	i.a.	i.a.	i.v.
Target Animal Safety
Pivotal study
Application to EMA			Second indication for BCX-CM-J
List of questions from EMA

BCX-CM-J

An allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in dogs.

BCX-CM-AD

An allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs.

BCX-EM

An allogeneic stem cell-based medicinal product developed for the treatment of osteoarthritis in horses.

BCX-CM-Sec

A research project aimed at developing a cell-free biological drug effective in treating atopic dermatitis in dogs.